FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1480-1482 April 10, 2003 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Siddiqui, A. PubMed Citation

Failure to respond to antiseizure drugs is the usual basis for defining intractable epilepsy, although there is a lack of consensus about what constitutes drug resistance and when this determination can be made.^1,2 At least 30 percent of patients with epilepsy in North America and western Europe continue to have seizures despite drug treatment.³ The figure may be even higher in adults with localization-related epilepsy.⁴ This situation has not changed despite the introduction of a number of antiseizure drugs in the past decade. Refractory epilepsy is associated with memory loss, lower levels of school performance, depression, impaired psychosocial skills, and . . . [Full Text of this Article]

Source Information

From the Department of Neurology, Columbia University, New York.

This article has been cited by other articles:

• Tan, N. C.K., Heron, S. E., Scheffer, I. E., Pelekanos, J. T., McMahon, J. M., Vears, D. F., Mulley, J. C., Berkovic, S. F. (2004). Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63: 1090-1092 [Abstract] [Full Text]